Key points are not available for this paper at this time.
CMS classification enhances CRC prognosis and treatment personalization but faces challenges due to ITH and technical limitations. Advances in IHC, imCMS, and targeted gene panels may facilitate broader clinical adoption, improving patient outcomes through tailored therapies.
Kantha et al. (Mon,) studied this question.